Related Experiment Videos
alpha4beta2 nACh receptor pharmacophore models
Richard A Glennon1, Małgorzata Dukat
1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA. glennon@hsc.vcu.edu
Bioorganic & Medicinal Chemistry Letters
|March 31, 2004
Summary
This review covers the evolution of alpha4beta2 nicotinic receptor pharmacophore models, from early concepts to advanced vector approaches for drug development.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Neuroscience
Background:
- The alpha4beta2 nicotinic acetylcholine receptor (nAChR) is a key target for neurological disorders.
- Developing selective pharmacophores for this receptor is crucial for therapeutic intervention.
Purpose of the Study:
- To review the historical development of alpha4beta2 nAChR pharmacophore models.
- To compare early models with contemporary vector-based approaches.
Main Methods:
- Literature review of published pharmacophore models for alpha4beta2 nAChRs.
- Analysis of the progression from 2D to 3D and vector-based modeling strategies.
Main Results:
- Early models, such as the Beers and Riech model, provided foundational insights.
- Newer vector models offer enhanced accuracy and predictive power for ligand design.
Conclusions:
- Pharmacophore modeling has significantly advanced for alpha4beta2 nAChRs.
- Vector models represent the current state-of-the-art for designing novel nAChR-targeting compounds.